Steroid Formulations for Cataract Treatment via Protein Aggregation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cataracts, including congenital cataracts, are largely surgical and invasive, lacking effective non-surgical alternatives that address the underlying protein aggregation mechanisms leading to lens opacity.
Innovation Solution
Development of novel ophthalmic compositions combining steroids such as lanosterol and its derivatives, including prodrugs like methyl esters, to prevent and treat cataracts by inhibiting protein aggregation and improving lens transparency, specifically targeting mutations in γC-crystallin associated with autosomal dominant congenital cataracts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical treatment is used to remove cataractous lenses, then cataracts are effectively treated, but the risk of complications increases and the treatment becomes invasive
Solution Approach 1:
The patent uses sterols (lanosterol, cholesterol, and their derivatives) as intermediary substances that mediate between the cataractous lens proteins and the desired therapeutic effect. These sterols act as pharmacological chaperones that bind to mutant crystallins and restore their solubility and transparency without requiring surgical intervention, thereby achieving treatment effectiveness while avoiding surgical complications.
Solution Approach 2:
The patent replaces the mechanical surgical approach (physical removal of the lens) with a biochemical approach using sterol compounds. Instead of mechanically extracting the cataractous lens, the treatment uses chemical substances (sterols) to dissolve and disperse the aggregated proteins in situ, transforming a mechanical intervention into a biochemical solution that achieves the same therapeutic goal without surgical risks.
2Ease of operation
If no non-surgical treatment is available, then cataracts can be treated, but effective non-invasive alternatives are lacking
Solution Approach 1:
The sterols serve as intermediary agents that enable non-invasive treatment while maintaining effectiveness. These molecules penetrate the lens and interact with mutant crystallins to restore transparency, providing a bridge between the non-invasive administration route and the effective therapeutic outcome that was previously only achievable through surgery.
Solution Approach 2:
The patent changes the physical and chemical parameters of the lens system by introducing sterols that alter the solubility and aggregation state of crystallin proteins. This parameter change (from aggregated opaque state to dissolved transparent state) achieves effective cataract treatment through non-invasive topical or systemic administration, eliminating the need for surgical intervention.
3Reliability
If protein aggregation is not inhibited, then lens opacity develops, but underlying protein aggregation mechanisms are not addressed
Solution Approach 1:
The sterols act as intermediary molecules that specifically target and interact with the aggregated protein structures. These sterol-chaperone molecules bind to mutant crystallins and facilitate their dissolution, directly addressing the protein aggregation mechanism while restoring lens transparency. This intermediary approach simplifies the complex protein aggregation problem into a manageable molecular interaction that can be therapeutically targeted.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The steroid formulations effectively reduce cataract severity, increase lens clarity, and inhibit protein aggregation, offering a non-invasive treatment option that can significantly improve or reverse cataract conditions, as demonstrated in both in vitro and in vivo studies.
Implementation Method 1
Zhao et al. identified lanosterol as an important compound in the prevention of lens protein aggregation and suggested a novel strategy for cataract prevention and treatment. Makley et al. reported the administration of certain sterols as pharmacological chaperones for α-crystallin for partially restoring transparency in cataract models.
Implementation Method 2
Treatment by lanosterol, but not cholesterol, significantly decreased preformed protein aggregates both in vitro and in cell-transfection experiments. The steroid formulations effectively reduce cataract severity, increase lens clarity, and inhibit protein aggregation.
Data Source
AI summary
In one embodiment, the present application discloses an aqueous ophthalmic composition for the treatment of eye diseases, lesions and injuries, comprising: a) one steroid, or a combination of at least two steroids selected from the group consisting of lanosterol, dihydrolanosterol, 4,4-dimethylcholesta-8(9),14,24-trien-3β-ol, 4,4-dimethylcholesta-8,24-dien-3β-ol, 4,4-dimethylcholesta-8-en-3β-ol, 4,4-dimethylcholesta-8(9),14-dien-3β-ol, 14-desmethyl lanosterol, lathosterol, Δ7,24-cholestadienol, cholesterol, cholesta-7-enol, cholesteryl ester, 7-dehydrocholesterol, desmosterol, 7-dehydrodesmosterol, zymosterol, 27-hydroxycholesterol, cholesta-7,24-dien-3-β-ol, cholesta-8(9)-en-3-β-ol, 5α-cholestan-3β-ol-6-one, 5-cholesten-3β,25-diol, 5-cholesten-3β,25-OSO3H (5-cholesten-3β,25-sulfate), 5-cholesten-3β-OSO3H,25-ol (5-cholesten-3β-sulfate,25-ol), 5-cholesten-3β,25-diol, disulfate, and their esters thereof, or a pharmaceutically acceptable salt thereof, in a concentration effective for the treatment and/or prophylaxis of the eye diseases, lesions and injuries; and b) a pharmaceutical excipient; and methods of treatment using such compositions.